



Review

Mcl-1; the molecular regulation of protein function

Luke W. Thomas, Connie Lam, Steven W. Edwards*

School of Biological Sciences, University of Liverpool, Liverpool L69 7ZB, UK

ARTICLE INFO

Article history:

Received 26 March 2010

Revised 25 May 2010

Accepted 28 May 2010

Available online 11 June 2010

Edited by Vladimir Skulachev

Keywords:

Apoptosis

Post-translational modification

Myeloid cell leukemia 1

Phosphorylation

ABSTRACT

Apoptosis, an essential and basic biological phenomenon, is regulated in a complex manner by a multitude of factors. Myeloid cell leukemia 1 (Mcl-1), an anti-apoptotic member of the B-cell lymphoma 2 (Bcl-2) family of apoptosis-regulating proteins, exemplifies a number of the mechanisms by which a protein's contribution to cell fate may be modified. The N-terminus of Mcl-1 is unique amongst the Bcl-2 family, in that it is rich in experimentally confirmed and putative regulatory residues and motifs. These include sites for ubiquitination, cleavage and phosphorylation, which influence the protein's stability, localisation, dimerization and function. Here we review what is known about the regulation of Mcl-1 expression and function, with particular focus on post-translational modifications and how phosphorylation interconnects the complex molecular control of Mcl-1 with cellular state.

© 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

1. Introduction

The term 'apoptosis' was first coined by Kerr, Wyllie and Currie in 1972, when they used live-cell imaging to make detailed observations of the dynamic behaviour of cells and tissues in culture. The observed morphological changes were identical in all cells undergoing apoptosis, which gave rise to the idea that this form of cell death is genetically programmed in each cell. Apoptosis has since been identified as a crucial process, in physiological terms, for a number of reasons: for the maintenance of tissue homeostasis, for the safe removal of unwanted or damaged cells, for morphogenesis during embryonic development, and for the resolution of inflammation. The culmination of apoptosis involves the activation of a family of cysteine proteases, named caspases,

which are responsible for the dismantling of the cell's components, that are then packaged into smaller apoptotic bodies to be cleared by phagocytes. The activation of caspases is tightly regulated at multiple levels, and mammalian cells have evolved mechanisms whereby a cell may intrinsically regulate its own fate, or be extrinsically induced to undergo apoptosis. The two pathways share a number of molecular components, including the B-cell lymphoma 2 (Bcl-2) family – a group of proteins whose role lies in regulating mitochondrial integrity (Fig. 1). There are now 20 or so known family members, which are identified by having sequence homology to the eponymous Bcl-2 protein at one or more regions, named Bcl-2 homology (BH) domains. The family is sub-divided according to the functional contribution that each protein makes to the progression of apoptosis, with both pro-survival, and pro-apoptotic proteins, and it is the balance in activity between these opposing groups which determines a cell's progression towards apoptosis. The current state of knowledge about the Bcl-2 family is reviewed in detail elsewhere [1,2].

2. Mcl-1 – discovery and characterisation

Mcl-1 (myeloid cell leukemia 1) is a pro-survival member of the Bcl-2 family that was initially identified as an immediate-early gene expressed during PMA-induced differentiation of ML-1 myeloid leukemia cells [3]. Alignment algorithms identified sequence similarity to the recently discovered pro-survival protein Bcl-2, and so Mcl-1 constituted only the second of this protein family when it was discovered. The Bcl-2 family represented a new class of oncogenes that promoted oncogenesis, not through upregulation

Abbreviations: MCL-1, myeloid cell leukemia 1; BCL-2, B-cell lymphoma 2; BH, Bcl-2 homology; BCL-X_L, Bcl-2 like protein X; BID, BH3 interacting domain death agonist; PUMA, p53 upregulated modulator of apoptosis; BAX, Bcl-2-associated protein X; BAK, Bcl-2 homologous antagonist killer; BFL-1/A1, Bcl-2 related protein A1; PEST, proline/glutamic acid/serine/threonine; CDK-1, cyclin dependent kinase 1; PCNA, proliferating cell nuclear antigen; CHK-1, checkpoint 1 protein; IL, interleukin; GM-CSF, granulocyte-macrophage colony-stimulating factor; VEGF, vascular endothelial growth factor; STAT, signal transducers and activators of transcription; SRE, STAT response element; CRE, cAMP response element; NF-κB, nuclear factor kappa B; CREB, cAMP response element binding protein; HIF-1α, hypoxia-inducible factor 1α; Mir-29b, micro inhibiting RNA 29b; MULE, MCL-1 ubiquitin ligase; β-TrCP, beta transducin-containing protein; GrB, granzyme B; JNK, C-Jun N-terminal kinase; ERK, extracellular regulated protein kinase; Pin-1, peptidyl-prolyl cis-trans isomerase NIMA interacting protein 1; CHX, cycloheximide

* Corresponding author. Address: Biosciences Building, School of Biological Sciences, University of Liverpool, Liverpool L69 7ZB, UK. Fax: +44 151 795 4414.

E-mail address: S.W.Edwards@liv.ac.uk (S.W. Edwards).




Fig. 1. Interactions of the Bcl-2 family. Bax [1a], a cytosolic protein, and Bak [1b], an integral mitochondrial membrane protein, are retained in monomeric forms by association with various anti-apoptotic Bcl-2 family members. This repression may be relieved by competitive inhibition from ‘inactivator’ BH3-only proteins, (iBH3) such as Bad and Noxa. Free cytosolic Bax [2], or free mitochondrial-membrane bound Bak require further association with ‘activator’ BH3-only proteins (aBH3) to induce a conformational change, and in the case of Bax, for effective mitochondrial targeting. aBH3-only proteins [3] are themselves prevented from associating with Bax and Bak by inhibitory association with anti-apoptotic Bcl-2 family members such as Mcl-1. As with Bax and Bak, the aBH3-only proteins may be freed by competitive inhibition from iBH3-only proteins. The conformational change of Bax and Bak [4] permits homo-oligomerisation of the proteins, and the formation of outer-mitochondrial membrane spanning pores. These Bax and Bak pores permit the release of cytochrome c into the cytoplasm, which triggers activation of the caspase cascade, and ultimately apoptosis.

of proliferation, but by maintaining viability through inhibition of apoptosis [4]. As predicted, dysregulation of Bcl-2 protein family expression and function has since been implicated in virtually all malignancies, and a number of other pathologies.

Sequence analysis revealed that while Mcl-1 contained 3 putative BH domains, and experimentally could protect against apoptosis, its large N-terminal region contained potential regulatory motifs that could be predicted to regulate its function (Fig. 2). Mcl-1 differs from its pro-survival relatives in its larger size of 350 residues, as compared to Bcl-2 at 239 residues (Fig. 2) and Bcl-2 like protein X (Bcl-X_L) at 233 residues. Residues 170–300 of Mcl-1 share a great deal of structural and functional homology to both Bcl-2 and Bcl-X_L, containing its three BH domains (Bcl-2 and Bcl-X possess 4), which confer the ability to heterodimerize with other family members [5]. The three solution structures of Mcl-1 that have been published each use N-terminally truncated forms of the protein, the first study with Mcl-1 as a monomer [6], the second two studies as dimers with the BH3-domains of

the pro-apoptotic proteins BH3 interacting domain death agonist (BID) [7] and p53 upregulated modulator of apoptosis (Puma) and Noxa [8], respectively. All three studies show that Mcl-1 has a similar structure to its pro-survival relatives, with a surface-exposed hydrophobic groove for the binding of other BH3-domain containing proteins. Mcl-1 blocks the progression of apoptosis by binding and sequestering the pro-apoptotic proteins Bcl-2 homologous antagonist killer (Bak) and Bcl-2-associated protein X (Bax), which are capable of forming pores in the mitochondrial membrane, allowing the release of cytochrome c into the cytoplasm. In the cytoplasm, cytochrome c induces the activation of a family of cysteine proteases named caspases which are responsible for much of the macromolecular degradation observed during apoptosis. Mcl-1 also binds and sequesters a subset of the BH3-only pro-apoptotic Bcl-2 family members, which act to induce the polymerisation of Bak and Bax. The repression of Bak and Bax polymerisation by Mcl-1 can be relieved both by the degradation of Mcl-1, and by its interaction with a second subset of the BH3-only




Fig. 2. The molecular organization of Mcl-1. A schematic representation of the Mcl-1 protein, to scale, with the relative positions of the functional regions and sites of post-translational modification highlighted. These include the transmembrane domain (TM), the Bcl-2 homology domains (numbered 1–4), two weak (lower case) and two strong (upper case) PEST sequences. Sites of post-translational modification are also shown, including ubiquitination (Ub), caspase cleavage (Casp), and phosphorylation (Phos). A schematic of a representative selection of other members of the Bcl-2 family are shown below, to scale, to compare the relative sizes and molecular organization of the proteins.

pro-apoptotic Bcl-2 family members, which induce dissociation of Bak and Bax from Mcl-1. In the C-terminal portion of Mcl-1 there is also a transmembrane domain, deletion of which blocks membrane insertion and localisation of the protein [9]. Some clues about the molecular basis of the functional non-redundancy of the Bcl-2 family were brought to light using these binding studies, which showed differences in the dimerisation pairs made by the pro-survival family members. Mcl-1, along with Bcl-2 related protein A1 constituted a subset which bound strongly to Noxa but only weakly to Bad, while Bcl-2, Bcl-w and Bcl-X_L bound strongly to Bad, but only weakly to Noxa. Additionally, the BH3-only proteins Bim and Puma bound promiscuously to all the pro-survival proteins, and Mcl-1 and Bcl-X_L have also been shown to preferentially bind Bak, whereas Bcl-2 does not [7]. The fine details of the Bcl-2 family interactions will continue to be uncovered, but the principal of partial non-redundancy is clear, and highlights the complexity of apoptosis regulation in multicellular organisms.

Much less is known about the non-Bcl-2-homologous N-terminal portion of the protein, approximately encompassing residues 1–170, which is predicted to have low-structural complexity, but is rich in confirmed and putative regulatory motifs. Indeed, since its discovery, the molecular characteristics of the N-terminus of Mcl-1 have been under scrutiny, with Kozopas et al. identifying enrichment of this region with proline (P), glutamic acid (E), serine (S) and threonine (T) residues, which earned this half of the protein its name as the ‘proline/glutamic acid/serine/threonine (PEST) region’ [3]. PEST enrichment and arginine pairs (of which Mcl-1 has four) are common features of labile proteins, and Kozopas et al. later confirmed this prediction in a study using pulse-chase

techniques [10]. The constitutive half-life of Mcl-1 is the subject of some uncertainty since the protein’s turnover may be shortened or lengthened significantly depending on the cellular conditions, and varies between cell types. Factors which influence the turnover of Mcl-1 are numerous and varied, and an exhaustive list is beyond the scope of this review. As expected however, those agents and conditions which delay Mcl-1 degradation tend to enhance cellular viability – such as trophic factors – and conversely, agents and conditions which accelerate Mcl-1 degradation act to decrease cellular viability – such as trophic factor withdrawal, or DNA damage.

3. Mcl-1 – expression and physiological function

Despite an initial appearance of functional redundancy between individual Bcl-2 family members, differences in both tissue distribution and function have been identified, and are reviewed elsewhere [11]. Mcl-1, like its Bcl-2 relatives, is widely expressed but has its own particular tissue distribution [10,12] along with its own specific physiological roles. Numerous, diverse cell-types have been shown to be reliant on Mcl-1 for their survival and development. For example, Mcl-1 deletion is peri-implantation lethal in mouse embryogenesis [13], whereas Bcl-2 deletion is not [14]. Mcl-1 has also been shown to be required for the development and maintenance of B and T-lymphocytes [15], and is also required for neural development [16]. It has also been shown to play a critical role in the regulation of macrophage and neutrophil apoptosis [17,18], and is essential for the survival of haematopoietic stem cells [19] and synovial fibroblasts [20]. Along with its roles in differentiation and apoptosis, Mcl-1 (like its Bcl-2 counterparts [21])

is also known to delay cell-cycle progression through interactions with cyclin dependent kinase 1 (CDK-1) [22], proliferating cell nuclear antigen (PCNA) [23] and checkpoint 1 protein (CHK-1) [24].

Initial studies of Mcl-1 identified that its expression was growth-factor dependent in many situations, and that it was capable of protecting cells from growth factor withdrawal-induced apoptosis [25]. A growing list of trophic factors have been shown to induce transcriptional upregulation of Mcl-1, including cytokines such as interleukin (IL)-3 [26], IL-5 [27], IL-6 [28], and granulocyte-macrophage colony-stimulating factor (GM-CSF) [29], as well as growth factors such as epidermal growth factor (EGF) [30] and vascular endothelial growth factor (VEGF) [31]. Intracellular regulation of Mcl-1 transcription is mediated by a number of externally activated and constitutively activated transcription factors, notably the signal transducers and activators of transcription (STAT) family. The promoter region of Mcl-1, characterised by Akgul et al. [32], contains an array of putative and confirmed transcription factor binding sites, including consensus STAT response elements, cAMP response elements (CRE), and nuclear factor kappa B binding sites. Both STAT3, in response to IL-6 [33], VEGF [34] and IL-3 [26], and STAT5, in response to Bcr-Abl signalling in chronic myeloid leukemia, have been shown to upregulate Mcl-1 transcription. Indeed, it has been suggested that STAT3 activation by phosphorylation is absolutely required for Mcl-1 mediated macrophage survival [35]. Other confirmed transcription factors known to upregulate Mcl-1 expression include cAMP response element binding protein [26], PU.1 [36] SP1 [37], and under hypoxic conditions, hypoxia-inducible factor 1 α [38]. Conversely, Mcl-1 may be down-regulated transcriptionally under a number of conditions, particularly under growth factor withdrawal [29], and on the induction of apoptosis induced by a variety of treatments, including staurosporine [39] and UV exposure [40]. In most cases, down-regulation is mediated by inactivation of the transcription factors stimulating Mcl-1 transcription, but the Mcl-1 promoter is directly repressed by the binding of the E2F-1 transcription factor (Fig. 3) [41].

In addition to transcriptional regulation, Mcl-1 is also subject to post-transcriptional and translational control. The mRNA of Mcl-1 can be alternatively spliced to remove exon 2, which produces a shortened form of Mcl-1, namely Mcl-1_S, which lacks BH domains 1, 2 and the transmembrane domain. A second, shorter, splice variant, named Mcl-1_{ES} has also been identified which lacks a portion of exon 1, removing 53 amino acids from the PEST region, but retains all three BH domains and the C-terminal transmembrane domain [42]. These shortened forms are unable to interact and sequester the pro-apoptotic Bcl-2 family members, and in fact induce apoptosis by binding and inhibiting full length Mcl-1 [43]. Upregulation of Mcl-1_S has been identified in macrophages during infection, and this appears to be an important mechanism for the successful resolution of inflammation [44]. The rate of Mcl-1 translation is also tightly regulated, and Mcl-1 mRNA, like the protein, has been shown to have a very short half-life. Mcl-1 mRNA translation is inhibited both by binding of the micro RNA, micro inhibiting RNA 29b [45] and the RNA binding protein CUGBP2 [46] at the 3'-UTR. Overexpression of either of these inhibitors of Mcl-1 translation dampens proliferation and induces apoptosis.

4. Contribution to pathophysiology

Well-regulated apoptosis is an essential process in development, tissue homeostasis and the regulation of inflammation, conversely dysregulation of apoptosis has wide-ranging influences in a number of pathophysiologicals [47]. Excessive apoptosis is implicated in a number of neurodegenerative diseases such as Alzheimer's [48] and multiple sclerosis [49], while evasion of apoptosis is a cardinal step in oncogenesis [50] and many inflammatory

conditions [47]. Mcl-1 overexpression has been reported in several haematological cancers [51–53] and solid tumours [54–56], including chronic myeloid leukemia and hepatocellular carcinoma. It has also been implicated in the chemoresistance of certain malignancies [56–58], notably against the first of a new class of Bcl-2 family targeting compounds, named ABT-737 [59]. Forced overexpression of Mcl-1 in transgenic mice led to a significantly increased incidence of B-cell lymphoma [60], while forced Mcl-1 down-regulation is able to induce apoptosis in a number of cancer cell types [61]. Thus Mcl-1 is an attractive and potential therapeutic target in a number of malignancies, and is the focus of a number of studies (reviewed in [62]).

5. Molecular characteristics

As described above, Mcl-1 has a unique tissue expression and specialised roles in physiology and pathology that set it apart from other Bcl-2 family members. It appears that many of these unique properties are determined by the large N-terminal domain of Mcl-1, which contains many motifs that affect its rate of turnover, localisation and phosphorylation status. These post-translational modifications of Mcl-1 provide the protein with the ability to rapidly and reversibly respond to environmental signals, and switch cell fate from survival to apoptosis.

5.1. Degradation

The degradation of Mcl-1 was first attributed to the proteasome by Nijhawan et al. in HeLa cells exposed to UV irradiation [40], and later confirmed by our own group and others [63]. The lysine residues targeted for ubiquitination (Fig. 2) were then identified and characterised by Zhong et al., who also discovered a novel E3 ubiquitin-ligase responsible for the constitutive polyubiquitination of Mcl-1, which they named Mcl-1 Ubiquitin Ligase E3 (MULE) [64]. However Mcl-1 degradation during apoptosis may be further accelerated, both by activation of other ubiquitin ligases and cleavage by other proteases. A second E3-ligase which targets Mcl-1 has been identified by Ding et al., namely beta transducin-containing protein (β -TrCP), which polyubiquitinates and targets Mcl-1 for degradation following GSK-3 phosphorylation of Mcl-1 (discussed in greater detail later) [65]. Conversely, Mcl-1 has also recently been shown to be the target of a deubiquitinase, named USP9X, which stabilizes Mcl-1 by reversing its polyubiquitination [66].

Secondly, it was known that Mcl-1 was additionally subject to non-proteasomal degradation, particularly during the progression of apoptosis, and two groups simultaneously characterised the caspase-dependent cleavage of Mcl-1 at two distinct sites within the N-terminus (Fig. 2) [67,68]. Han et al. then identified Granzyme B (GrB) cleavage of Mcl-1 at the same two sites (and one other) during GrB-mediated apoptosis [69]. Cleavage of Mcl-1 at these sites unambiguously impairs the protein's ability to protect against apoptosis by inhibiting dimerisation with its cognate pro-apoptotic partners. However, some studies have reported that cleavage at these sites additionally converts Mcl-1 to a pro-apoptotic protein [67,70], although this has been disputed by others [68,71]. Nevertheless, it is clear that cleavage of Mcl-1 is an important process by which the contribution of Mcl-1 to cell viability may be rapidly regulated.

5.2. Localisation

Under resting conditions, Mcl-1 is localised to various cellular membranes, including the mitochondria [9,10] and nuclear envelope [72], but it also has prominent cytosolic localisation, presumably as a heterodimer with Bax, and in some studies has been




Fig. 3. Overview of the molecular regulation of Mcl-1 [1]. Trophic signalling by cytokines and growth factors activates a number of transcription factors which stimulate Mcl-1 transcription, which can be repressed by the E2F-1 transcription factor [2]. Alternative splicing leads to the production of three mRNA species: full length (*mcl-1_L*), short (*mcl-1_S*) and extra short (*mcl-1_{ES}*). The latter two are unable to bind and sequester pro-apoptotic Bcl-2 family members, and instead bind and inactivate full length Mcl-1 [3]. Translation of full length Mcl-1 mRNA is negatively regulated by both the microRNA Mir-29b and the RNA binding protein CUGBP2 [4]. Pro-apoptotic extracellular signalling leads to the activation of caspase-8 which cleaves and activates Bid which binds and inactivates Mcl-1 [5]. Additionally, paracellularly secreted Granzyme B cleaves and inactivates Mcl-1 [6]. Mcl-1 is subject to constitutive degradation by the proteasome, and this may be accelerated or inhibited by phosphorylation at various residues, described in detail in later sections [7]. On the induction of apoptosis, the cascade of caspase activation is amplified by caspase-3 mediated cleavage and inactivation of Mcl-1.

localised to the nucleus [22,23,72]. Efficient targeting of Mcl-1 to the mitochondria has been shown to be dependent on both the first 79 residues of Mcl-1 [73], an internal EELD sequence (at residue 124–127), interaction with the Tom70 receptors [74] and the C-terminal transmembrane domain [9]. Indeed, the ability of Mcl-1 to localise to the mitochondria is necessary for it to counter the activity of the pro-apoptotic proteins Bak and Bax [73]. Nuclear localisation of Mcl-1 has been attributed to interactions with CDK-1 and PCNA, though the molecular regulation of these interactions and transport of Mcl-1 across the nuclear membrane is, as yet, unknown.

5.3. Phosphorylation

In the preceding part of this review, we have detailed the majority of mechanisms by which the function of Mcl-1 is regulated, and these mechanisms are themselves regulated by the phosphorylation of Mcl-1. Phosphorylation is an almost universal, rapid and

reversible modification of proteins that has wide-ranging influences on protein behaviour, including protein localisation, structure, protein–protein interactions, stability, the regulation of other protein modifications and protein function. Thus, phosphorylation serves to integrate a complex array of biological processes that may be complimentary, or in opposition to each other. The PEST region of Mcl-1 is rich in putative phosphorylation sites, and a number of these have been experimentally confirmed, and their influence on Mcl-1 behaviour have, in part, been elucidated. In the final part of this review, we detail those phosphoresidues of Mcl-1 that have been confirmed experimentally as well as describing their influence on Mcl-1 function (Figs. 4 and 5).

5.3.1. Serine 64

This phosphoresidue was identified and confirmed *in vivo* by Kobayashi et al. [75] using mass spectrometric analysis of a threonine 163 to alanine (T163A) mutant of Mcl-1. The residue was found to be phosphorylated by CDKs 1 and 2, and by C-Jun N-ter-




Fig. 4. Signalling pathways and Mcl-1 phosphorylation. A schematic diagram representing the confirmed signalling pathways and kinases that leads to the phosphorylation of Mcl-1. The influence that phosphorylation of each residue has on the stability of Mcl-1 (left panel) and the progression of apoptosis (right panel) is also shown, whether positively (+) or negatively (-) or if this is currently unknown (?).




Fig. 5. The phosphoresidues of Mcl-1. A schematic diagram of the Mcl-1 protein, to scale, summarising the experimentally confirmed phosphoresidues of Mcl-1, and the influence that each phosphorylation has on protein stability, dimerization and function.

minimal kinase (JNK), and also to be more strongly phosphorylated in the G_2/M phase of the cell-cycle than at the G_1/S boundary, suggesting that there is a cell cycle-dependency for Ser⁶⁴ phosphorylation. No significant differences in protein stability were found between wild-type Mcl-1 and phosphonegative (S64A) or phosphomimic (S64E) forms, suggesting that this residue does not influence the rate of Mcl-1 turnover. It was demonstrated that the S64A mutant of Mcl-1 had lower binding affinity for various pro-apoptotic members of the Bcl-2 family compared to the S64E phosphomimic mutant, and that this translated to a decreased ability to counter TRAIL-induced apoptosis.

5.3.2. Threonine 92

This phosphoresidue was identified by Ding et al. [76] using an in vitro extracellular regulated protein kinase-1 (ERK-1) kinase assay, with purified GST-tagged Mcl-1 as the substrate, followed by mass spectrometric analysis, and both Thr⁹² and Thr¹⁶³ were found to be simultaneously phosphorylated. It was found that a double T92/163A phosphonegative mutant of Mcl-1 was significantly less stable than the wild-type, and a double T92/163D phosphomimic mutant was significantly more stable. The authors then discovered that siRNA knockdown of the peptidyl-prolyl cis/trans isomerase, peptidyl-prolyl cis-trans isomerase NIMA interacting protein 1

(Pin-1), abrogated any increase in Mcl-1 stability induced by Erk-1 activation, which suggests that Erk-1 phosphorylation of these residues stabilizes Mcl-1 by promoting association with Pin-1. No direct assessment of the anti-apoptotic function of Thr⁹² phosphomutants was made, only inferentially using Pin1 siRNA knock-down, which led to a small increase in constitutive apoptosis, but also strongly sensitized the cells to Taxol and 5-fluorouracil induced apoptosis.

5.3.3. Serine 121

This phosphoresidue was identified by Inoshita et al. [77] in a study investigating the influence of oxidative stress on apoptosis, and also by Kodama et al. [78]. Inoshita et al. identified that phosphonegative mutation at Ser¹²¹ and Thr¹⁶³ abrogated the phosphorylation-dependent electrophoretic mobility shift of Mcl-1, induced by H₂O₂ treatment. Similarly, Kodama et al. discovered that the same phosphonegative mutation abrogated Ser/Thr phosphorylation of Mcl-1 in primary mouse hepatocytes. JNK was identified in both studies as the kinase responsible for phosphorylation at this residue. While Inoshita et al. did not detect any changes in Mcl-1 stability when Ser¹²¹ (in conjunction with Thr¹⁶³) was mutated, Kodama et al. found that in their model, a double S121A/T163A mutant of Mcl-1 was significantly less stable than the wild-type. Kodama et al. concluded that JNK phosphorylation of Mcl-1 at Ser¹²¹, in conjunction with Thr¹⁶³, stabilizes Mcl-1 and affords protection against TNF α -induced apoptosis. However, Inoshita et al. demonstrated in their study that a double phosphonegative S121A/T163A mutant of Mcl-1 was significantly more potent at inhibiting apoptosis induced by H₂O₂ treatment.

5.3.4. Serine 155

This phosphoresidue was identified by Ding et al. [65] in a study investigating the role of Glycogen Synthase Kinase (GSK) 3 in tumour apoptosis. Initially, they identified that GSK-3 inhibition, through either mutation or chemical means, led to an increase in Mcl-1 expression whereas expression of constitutively active GSK-3 decreased Mcl-1 expression. Using sequence analysis, the authors then identified two potential consensus GSK-3 β phosphorylation motifs (¹⁵⁰SGGNN¹⁵⁴T and ¹⁵⁵STDG¹⁵⁹SLPS¹⁶³T), but only phosphonegative mutation of the second, named Mcl-1-3A, abolished GSK-3 β mediated phosphorylation in an in vitro kinase assay. Phosphorylation at Ser¹⁵⁵ was then confirmed using phospho-specific antibodies (to Ser¹⁵⁵, Ser¹⁵⁹ and Thr¹⁶³), and it was found that GSK-3 β phosphorylated all three residues in the sequence, while under the same conditions ERK-1 phosphorylated only Thr¹⁶³. The authors also found that phosphonegative mutation of Ser¹⁵⁵ (in conjunction with Ser¹⁵⁹ and Thr¹⁶³) in the Mcl-1-3A mutant, stabilised Mcl-1 compared to the wild-type. Finally, the authors showed that the Mcl-1-3A mutant of Mcl-1 was significantly more potent at inhibiting the apoptosis of MCF-7 breast cancer cells induced by 5-fluorouracil, cisplatin and taxol, as compared to the wild-type.

5.3.5. Serine 159

The phosphorylation of serine 159 has been identified by three groups, Ding et al. [65] in the work described above, by Maurer et al. [79], and by Morel et al. [80]. All three studies identified GSK-3 as the kinase targeting this residue, and discovered that phosphorylation of this residue led to significant decrease in Mcl-1 protein expression. Morel et al. also identified that an initial ‘priming’ phosphorylation of Thr¹⁶³ (by JNK) was required for Ser¹⁵⁹ phosphorylation – a characteristic of other GSK-3 targets [81] – using sequential in vitro JNK and GSK-3 kinase assays. Both Morel et al. [80] and Maurer et al. [79] found that phosphonegative mutation of Ser¹⁵⁹ stabilized Mcl-1, following UV-irradiation or cycloheximide (CHX) treatment respectively. Ding et al. showed that ubiqui-

tion of Mcl-1 following Ser¹⁵⁹ phosphorylation was mediated by the E3 ubiquitin ligase β -TrCP, rather than MULE. Finally, Maurer et al. and Morel et al. both demonstrated that phosphonegative mutation of Mcl-1 at Ser¹⁵⁹ affords better protection against IL-3 withdrawal-induced apoptosis and UV irradiation-induced apoptosis respectively. Maurer et al. additionally showed that in the absence of IL-3 (in order to initiate apoptosis and a Bim:Mcl-1 interaction), Bim was only co-immunoprecipitated with Mcl-1 following treatment with the small-molecule inhibitor of GSK-3, CHIR-611. In conclusion, GSK-3 phosphorylation at Ser¹⁵⁹ both destabilizes Mcl-1 and inhibits the interaction of Mcl-1 with the pro-apoptotic protein, Bim, thus impairing its anti-apoptotic function.

5.3.6. Threonine 163

This residue was the first experimentally confirmed phosphoresidue of Mcl-1, in a study by Inoshita et al. [77], and is also the most highly investigated, having been confirmed twice by Ding et al. [65,76] and also by Domina et al. [82]. Inoshita et al. first identified Thr¹⁶³ as a strong candidate phosphoresidue from sequence analysis, and this was later repeated by Domina et al., who noted that the residue lies within a complete consensus MAP kinase phosphorylation sequence, and is highly conserved across species. Domina et al. identified this residue as a target for ERK-1 in response to TPA stimulation of CHO and BL41-3 cells, using ³²P incorporation assays, as well as utilising inhibitors of ERK. This observation was later confirmed in a study by Ding et al. using an in vitro ERK-1 kinase assay [76]. The influence of single Thr¹⁶³ phosphorylation on Mcl-1 stability was inferred by Domina et al. from two experiments. Firstly, TPA treatment significantly increased the stability of endogenous Mcl-1 in BL41-3 cells following treatment with CHX at 25 μ g/mL (88 μ M). Secondly, since mutation of threonine 163 to alanine abolished TPA-induced phosphorylation of Mcl-1, it was concluded that TPA-induced phosphorylation of Thr¹⁶³ stabilizes Mcl-1. It must be noted that this is seemingly contradicted by the results published by Inoshita et al. who concluded that phosphorylation of Thr¹⁶³ by JNK destabilized Mcl-1, though Domina et al. address this and point out that Inoshita et al. used a double S121A/T163A mutant in their stability experiments, which confounds any conclusions that may be drawn about Thr¹⁶³ phosphorylation alone. While Domina et al. made no investigation as to the influence of Thr¹⁶³ on the anti-apoptotic function of Mcl-1, other reports have done so, but only in conjunction with phosphorylation of other residues. Ding et al. inferred in one report that co-phosphorylation of Thr¹⁶³ with Thr⁹² by ERK-1 improves Mcl-1 function [76], and showed in a second that co-phosphorylation of Thr¹⁶³ with Ser¹⁵⁵ and Ser¹⁵⁹ by GSK-3 impairs its anti-apoptotic function [65]. Inoshita et al. similarly show that co-phosphorylation of Thr¹⁶³ with Ser¹²¹ ‘inactivates’ Mcl-1, and impairs its anti-apoptotic function in response to H₂O₂ treatment [77].

6. Discussion

Evidence is accumulating that Mcl-1 is a protein whose contribution to cell fate is rapidly and acutely regulated, through changes in transcription, localisation, stability and its ability to form dimers with Bcl-2 homologues and other proteins. Much of this flexibility in expression and anti-apoptotic function appears to be due to its unique (among the Bcl-2 family) and extensive N-terminal portion which contains a large number of modifiable residues, and therefore appears to act as a regulatory region. With such complex regulation of protein function at multiple levels, it is highly likely that these regulatory processes are context-based. For example, the regulatory mechanisms that operate in different cells and tissues

under varying conditions of stress or other environmental factors could lead to differential activation of kinase/phosphatase cascades, or alternative proteolytic pathways (e.g. calpains, proteasome, or caspases). It is also important to bear in mind that some regulatory mechanisms may be cell-cycle dependent. Thus, while the range of methodological approaches used to study Mcl-1 function may sometimes yield conflicting data, genuine variance in the mechanisms of Mcl-1 regulation may exist in cells and tissues under different pathophysiological conditions.

The published data detailed in this review highlights some important problems when attempting to piece together an accurate picture of the molecular regulation of Mcl-1 by phosphorylation. The gold-standard technique for confirmation of phosphorylation at a particular residue is mass-spectrometry. However, since sample preparation can be complicated, particularly for a low abundance protein such as Mcl-1, most groups resort to *in vitro* kinase assays of immunoprecipitated exogenously-expressed tagged forms of the protein. The second choice for confirmation of phosphorylation is with the use of phospho-specific antibodies, which have the added benefit of being usable for the detection of changes in relative levels of phosphorylation by immunoblotting. Finally, autoradiographic detection of ³²P incorporation into mutant forms of Mcl-1 is useful and has been widely used, but suffers from being a less direct and specific approach than either mass-spectrometry or phospho-specific antibodies.

More difficulties arise when comparing the data regarding the influence of phosphoresidues on the stability of Mcl-1. None of the stability experiments detailed here share the same experimental conditions, with wide variations in the cell-types, molecular characteristics of the Mcl-1 being assessed, expression systems, chemical treatments and data analyses used. While transient transfection of mutant forms of Mcl-1 is widely used and bypasses the technical challenges of creating stable transfectants, there is often no control for transfection efficiency, and sometimes no means of distinguishing between exogenously and endogenously expressed Mcl-1. The use of the translation inhibitor CHX is common, and yet the quoted working concentrations vary from 5 µg/mL to 5 mg/mL. This variation confounds comparison of the data from different studies, since there is a concentration-dependent effect of CHX treatment on the expression of labile proteins, and issues of cytotoxicity at higher concentrations (>30 µg/mL). In addition, most studies use doubly or triply mutated forms of Mcl-1, making it hard to elucidate the contribution of individual residues.

Nevertheless, some principals are clear from the literature. Firstly that phosphorylation at Thr¹⁶³ contributes to the stabilization and destabilization of Mcl-1 depending on the activity of other kinases. The literature currently highlights Thr¹⁶³ as one of, if not the key phosphoresidue in regulating the fate of Mcl-1, since it appears to be a necessary 'priming' site for phosphorylation of, or at least to be phosphorylated in conjunction with all other experimentally confirmed phosphoresidues, with the exception of Ser⁶⁴. Secondly, phosphorylation by GSK-3 at multiple residues is a key modification for the rapid degradation of Mcl-1. Thirdly that constitutive Erk-1 phosphorylation at Thr¹⁶³ stabilizes Mcl-1 under resting conditions. The influence of JNK phosphorylation is less clear, since it appears to be required at Thr¹⁶³ for the destabilizing phosphorylation of Ser¹⁵⁹ and Ser¹⁵⁵ by GSK-3, while also itself phosphorylating and stabilizing Mcl-1 at Ser¹²¹. Next, two studies have identified that phosphorylation of certain residues affects the degree of Mcl-1 ubiquitination [65,79], and thus it would appear that modification by phosphorylation leads to exposure or masking of lysine residues for binding and modification by ubiquitin ligases. And finally, while the N-terminal portion of the protein is predicted to have low-structural complexity, it evidently must play a role in regulating the binding of Mcl-1 to other proteins. Abrogat-

ing the phosphorylation of Ser¹⁵⁹ diminished the ability of Mcl-1 to associate with the BH3-only protein Bim, while the same treatment of Thr⁹² inhibited the association of Mcl-1 with Pin-1. Currently however, the only published solution structures of Mcl-1 are of N-terminally truncated forms of the protein [6,8], and so the exact steric behaviour of this portion of Mcl-1 is still unknown, though this will be of importance in understanding how its modification can influence Mcl-1 dimerization. Phosphorylation must also play a role in regulating the influence of Mcl-1 on the cell cycle – an exciting but underinvestigated feature of the Bcl-2 protein family. Phosphorylation of Ser⁶⁴ was found to have a cell-cycle dependency, and since Mcl-1 has been reported to bind to CDK1, PCNA and CHK-1 *in vivo* [22], it is tempting to hypothesise that phosphorylation of this residue may regulate the timing of these dimerisations.

These data highlight the multifactorial nature of the regulation of cell fate, and how proteins such as Mcl-1 intersect opposing and complimentary signalling cascades, and can effect changes in the balance between these signals.

Acknowledgements

We thank Leukemia and Lymphoma Research and Arthritis Research UK for financial support.

References

- [1] Adams, J.M. and Cory, S. (2007) The Bcl-2 apoptotic switch in cancer development and therapy. *Oncogene* 26 (9), 1324–1337.
- [2] Brenner, D. and Mak, T.W. (2009) Mitochondrial cell death effectors. *Curr. Opin. Cell Biol.* 21 (6), 871–877.
- [3] Kozopas, K.M. et al. (1993) MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. *Proc. Natl Acad. Sci. USA* 90 (8), 3516–3520.
- [4] Vaux, D.L., Cory, S. and Adams, J.M. (1988) Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. *Nature* 335 (6189), 440–442.
- [5] Lutz, R.J. (2000) Role of the BH3 (Bcl-2 homology 3) domain in the regulation of apoptosis and Bcl-2-related proteins. *Biochem. Soc. Trans.* 28 (2), 51–56.
- [6] Day, C.L. et al. (2005) Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands. *J. Biol. Chem.* 280 (6), 4738–4744.
- [7] Chen, L. et al. (2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. *Mol. Cell* 17 (3), 393–403.
- [8] Day, C.L. et al. (2008) Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1. *J. Mol. Biol.* 380 (5), 958–971.
- [9] Akgul, C. et al. (2000) *In vivo* localisation and stability of human Mcl-1 using green fluorescent protein (GFP) fusion proteins. *FEBS Lett.* 478 (1–2), 72–76.
- [10] Yang, T., Kozopas, K.M. and Craig, R.W. (1995) The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. *J. Cell Biol.* 128 (6), 1173–1184.
- [11] Sorenson, C.M. (2004) Bcl-2 family members and disease. *Biochim. Biophys. Acta* 1644 (2–3), 169–177.
- [12] Krajewski, S. et al. (1995) Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death *in vivo*. *Am. J. Pathol.* 146 (6), 1309–1319.
- [13] Rinkenberger, J.L. et al. (2000) Mcl-1 deficiency results in peri-implantation embryonic lethality. *Genes Dev.* 14 (1), 23–27.
- [14] Veis, D.J. et al. (1993) Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. *Cell* 75 (2), 229–240.
- [15] Opferman, J.T. et al. (2003) Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. *Nature* 426 (6967), 671–676.
- [16] Arbour, N. et al. (2008) Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage. *J. Neurosci.* 28 (24), 6068–6078.
- [17] Steimer, D.A. et al. (2009) Selective roles for antiapoptotic MCL-1 during granulocyte development and macrophage effector function. *Blood* 113 (12), 2805–2815.
- [18] Edwards, S.W. et al. (2004) Regulation of neutrophil apoptosis by Mcl-1. *Biochem. Soc. Trans.* 32 (Pt 3), 489–492.
- [19] Opferman, J.T. et al. (2005) Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. *Science* 307 (5712), 1101–1104.
- [20] Liu, H. et al. (2005) Mcl-1 is essential for the survival of synovial fibroblasts in rheumatoid arthritis. *J. Immunol.* 175 (12), 8337–8345.

- [21] Maddika, S. et al. (2007) Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. *Drug Resist. Update* 10 (1–2), 13–29.
- [22] Jamil, S. et al. (2005) A proteolytic fragment of Mcl-1 exhibits nuclear localization and regulates cell growth by interaction with Cdk1. *Biochem. J.* 387 (Pt 3), 659–667.
- [23] Fujise, K. et al. (2000) Regulation of apoptosis and cell cycle progression by MCL1. Differential role of proliferating cell nuclear antigen. *J. Biol. Chem.* 275 (50), 39458–39465.
- [24] Jamil, S. et al. (2008) An essential role for MCL-1 in ATR-mediated CHK1 phosphorylation. *Mol. Biol. Cell* 19 (8), 3212–3220.
- [25] Bodrug, S.E. et al. (1995) Biochemical and functional comparisons of Mcl-1 and Bcl-2 proteins: evidence for a novel mechanism of regulating Bcl-2 family protein function. *Cell Death Differ.* 2 (3), 173–182.
- [26] Wang, J.M. et al. (1999) The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. *Mol. Cell. Biol.* 19 (9), 6195–6206.
- [27] Huang, H.M., Huang, C.J. and Yen, J.J. (2000) Mcl-1 is a common target of stem cell factor and interleukin-5 for apoptosis prevention activity via MEK/MAPK and PI-3K/Akt pathways. *Blood* 96 (5), 1764–1771.
- [28] Jourdan, M. et al. (2000) Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. *Cell Death Differ.* 7 (12), 1244–1252.
- [29] Chao, J.R. et al. (1998) Mcl-1 is an immediate-early gene activated by the granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling pathway and is one component of the GM-CSF viability response. *Mol. Cell. Biol.* 18 (8), 4883–4898.
- [30] Leu, C.M., Chang, C. and Hu, C. (2000) Epidermal growth factor (EGF) suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway. *Oncogene* 19 (13), 1665–1675.
- [31] Le Gouill, S. et al. (2004) VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. *Blood* 104 (9), 2886–2892.
- [32] Akgul, C. et al. (2000) Functional analysis of the human MCL-1 gene. *Cell. Mol. Life Sci.* 57 (4), 684–691.
- [33] Puthier, D., Bataille, R. and Amiot, M. (1999) IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. *Eur. J. Immunol.* 29 (12), 3945–3950.
- [34] Lee, Y.K. et al. (2005) VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. *Leukemia* 19 (4), 513–523.
- [35] Liu, H. et al. (2003) Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival. *Blood* 102 (1), 344–352.
- [36] Wang, J.M., Lai, M.Z. and Yang-Yen, H.F. (2003) Interleukin-3 stimulation of mcl-1 gene transcription involves activation of the PU.1 transcription factor through a p38 mitogen-activated protein kinase-dependent pathway. *Mol. Cell. Biol.* 23 (6), 1896–1909.
- [37] Townsend, K.J. et al. (1999) Regulation of MCL1 through a serum response factor/Elk-1-mediated mechanism links expression of a viability-promoting member of the BCL2 family to the induction of hematopoietic cell differentiation. *J. Biol. Chem.* 274 (3), 1801–1813.
- [38] Liu, X.H. et al. (2006) HIF-1 α has an anti-apoptotic effect in human airway epithelium that is mediated via Mcl-1 gene expression. *J. Cell. Biochem.* 97 (4), 755–765.
- [39] Iglesias-Serret, D. et al. (2003) Transcriptional and translational control of Mcl-1 during apoptosis. *Arch. Biochem. Biophys.* 417 (2), 141–152.
- [40] Nijhawani, D. et al. (2003) Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. *Genes Dev.* 17 (12), 1475–1486.
- [41] Croxton, R. et al. (2002) Direct repression of the Mcl-1 promoter by E2F1. *Oncogene* 21 (9), 1359–1369.
- [42] Kim, J.H. et al. (2009) MCL-1ES, a novel variant of MCL-1, associates with MCL-1L and induces mitochondrial cell death. *FEBS Lett.* 583 (17), 2758–2764.
- [43] Bae, J. et al. (2000) MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. *J. Biol. Chem.* 275 (33), 25255–25261.
- [44] Marriotti, H.M. et al. (2005) Dynamic changes in Mcl-1 expression regulate macrophage viability or commitment to apoptosis during bacterial clearance. *J. Clin. Invest.* 115 (2), 359–368.
- [45] Mott, J.L. et al. (2007) Mir-29 regulates Mcl-1 protein expression and apoptosis. *Oncogene* 26 (42), 6133–6140.
- [46] Subramaniam, D. et al. (2008) Translation inhibition during cell cycle arrest and apoptosis: Mcl-1 is a novel target for RNA binding protein CUGBP2. *Am. J. Physiol. Gastrointest. Liver Physiol.* 294 (4), G1025–G1032.
- [47] Fadeel, B. and Orrenius, S. (2005) Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. *J. Intern. Med.* 258 (6), 479–517.
- [48] Rohn, T.T., The role of caspases in Alzheimer's disease; potential novel therapeutic opportunities. Apoptosis. <http://www.springerlink.com/content/p27q523882g4238r/>.
- [49] Das, A. et al. (2008) Activation of calpain and caspase pathways in demyelination and neurodegeneration in animal model of multiple sclerosis. *CNS Neurol. Disord.: Drug Targets* 7 (3), 313–320.
- [50] Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. *Cell* 100 (1), 57–70.
- [51] Aichberger, K.J. et al. (2005) Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. *Blood* 105 (8), 3303–3311.
- [52] Le Gouill, S. et al. (2004) Mcl-1 regulation and its role in multiple myeloma. *Cell Cycle* 3 (10), 1259–1262.
- [53] Breitenbuecher, F. et al. (2009) A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. *Blood* 113 (17), 4063–4073.
- [54] Fleischer, B. et al. (2006) Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma. *Int. J. Oncol.* 28 (1), 25–32.
- [55] Henson, E.S., Hu, X. and Gibson, S.B. (2006) Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. *Clin. Cancer Res.* 12 (3 Pt 1), 845–853.
- [56] Song, L. et al. (2005) Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. *Cancer Biol. Ther.* 4 (3), 267–276.
- [57] Fu, J.R. et al. (2005) The effects of Mcl-1 gene on ATRA-resistant HL-60 cell. *Zhonghua Xue Ye Xue Za Zhi* 26 (6), 352–354.
- [58] Thallinger, C. et al. (2004) Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide. *Clin. Cancer Res.* 10 (12 Pt 1), 4185–4191.
- [59] van Delft, M.F. et al. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. *Cancer Cell* 10 (5), 389–399.
- [60] Zhou, P. et al. (2001) MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. *Blood* 97 (12), 3902–3909.
- [61] Moulding, D.A. et al. (2000) Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 cells. *Blood* 96 (5), 1756–1763.
- [62] Akgul, C. (2009) Mcl-1 is a potential therapeutic target in multiple types of cancer. *Cell. Mol. Life Sci.* 66 (8), 1326–1336.
- [63] Derouet, M. et al. (2004) Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1. *J. Biol. Chem.* 279 (26), 26915–26921.
- [64] Zhong, Q. et al. (2005) Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. *Cell* 121 (7), 1085–1095.
- [65] Ding, Q. et al. (2007) Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. *Mol. Cell. Biol.* 27 (11), 4006–4017.
- [66] Schwickart, M. et al. (2010) Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. *Nature* 463 (7277), 103–107.
- [67] Weng, C. et al. (2005) Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. *J. Biol. Chem.* 280 (11), 10491–10500.
- [68] Clohessy, J.G., Zhuang, J. and Brady, H.J. (2004) Characterisation of Mcl-1 cleavage during apoptosis of haematopoietic cells. *Br. J. Haematol.* 125 (5), 655–665.
- [69] Han, J. et al. (2004) Degradation of Mcl-1 by granzyme B: implications for Bim-mediated mitochondrial apoptotic events. *J. Biol. Chem.* 279 (21), 22020–22029.
- [70] Herrant, M. et al. (2004) Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. *Oncogene* 23 (47), 7863–7873.
- [71] Han, J. et al. (2005) Disruption of Mcl-1/Bim complex in granzyme B-mediated mitochondrial apoptosis. *J. Biol. Chem.* 280 (16), 16383–16392.
- [72] Leuenroth, S.J. et al. (2000) The loss of Mcl-1 expression in human polymorphonuclear leukocytes promotes apoptosis. *J. Leukoc. Biol.* 68 (1), 158–166.
- [73] Germain, M. and Duronio, V. (2007) The N terminus of the anti-apoptotic BCL-2 homologue MCL-1 regulates its localization and function. *J. Biol. Chem.* 282 (4), 32233–32242.
- [74] Chou, C.H., Lee, R.S. and Yang-Yen, H.F. (2006) An internal EELD domain facilitates mitochondrial targeting of Mcl-1 via a Tom70-dependent pathway. *Mol. Biol. Cell* 17 (9), 3952–3963.
- [75] Kobayashi, S. et al. (2007) Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. *J. Biol. Chem.* 282, 18407–18417.
- [76] Ding, Q. et al. (2008) Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. *Cancer Res.* 68 (15), 6109–6117.
- [77] Inoshita, S. et al. (2002) Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. *J. Biol. Chem.* 277 (46), 43730–43734.
- [78] Kodama, Y. et al. (2009) Antiapoptotic effect of c-Jun N-terminal kinase-1 through Mcl-1 stabilization in TNF-induced hepatocyte apoptosis. *Gastroenterology* 136 (4), 1423–1434.
- [79] Maurer, U. et al. (2006) Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. *Mol. Cell* 21 (6), 749–760.
- [80] Morel, C. et al. (2009) Mcl-1 integrates the opposing actions of signaling pathways that mediate survival and apoptosis. *Mol. Cell. Biol.* 29 (14), 3845–3852.
- [81] Doble, B.W. and Woodgett, J.R. (2003) GSK-3: tricks of the trade for a multi-tasking kinase. *J. Cell Sci.* 116 (Pt 7), 1175–1186.
- [82] Domina, A.M. et al. (2004) MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. *Oncogene* 23 (31), 5301–5315.